Biomea Fusion, Inc. reported positive findings from its Phase II COVALENT-111 diabetes study on October 6, 2025, showing a durable HbA1c reduction of 1.2% after 52 weeks of treatment with icovamenib. Significant improvements were noted especially in patients with severe insulin deficiencies, reinforcing the drug's potential for effective diabetes management.